Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma

Sattva S. Neelapu; Sherry Adkins; Stephen M. Ansell; Joshua Brody; Mitchell S. Cairo; Jonathan W. Friedberg; Justin P. Kline; Ronald Levy; David L. Porter; Koen Van Besien; Michael Werner; Michael R. Bishop

doi:10.1136/jitc-2020-001235

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma

Sattva S. Neelapu, Sherry Adkins, Stephen M. Ansell, Joshua Brody, Mitchell S. Cairo, Jonathan W. Friedberg, Justin P. Kline, Ronald Levy, David L. Porter, Koen Van Besien, Michael Werner, Michael R. Bishop

Lymphoma-Myeloma

Research output: Contribution to journal › Review article › peer-review

11 Scopus citations

Abstract

The recent development and clinical implementation of novel immunotherapies for the treatment of Hodgkin and non-Hodgkin lymphoma have improved patient outcomes across subgroups. The rapid introduction of immunotherapeutic agents into the clinic, however, has presented significant questions regarding optimal treatment scheduling around existing chemotherapy/radiation options, as well as a need for improved understanding of how to properly manage patients and recognize toxicities. To address these challenges, the Society for Immunotherapy of Cancer (SITC) convened a panel of experts in lymphoma to develop a clinical practice guideline for the education of healthcare professionals on various aspects of immunotherapeutic treatment. The panel discussed subjects including treatment scheduling, immune-related adverse events (irAEs), and the integration of immunotherapy and stem cell transplant to form recommendations to guide healthcare professionals treating patients with lymphoma.

Original language	English (US)
Article number	e001235
Journal	Journal for immunotherapy of cancer
Volume	8
Issue number	2
DOIs	https://doi.org/10.1136/jitc-2020-001235
State	Published - Dec 24 2020

Keywords

antineoplastic protocols
guidelines as topic
hematologic neoplasms
immunotherapy

ASJC Scopus subject areas

Immunology and Allergy
Immunology
Molecular Medicine
Oncology
Pharmacology
Cancer Research

Access to Document

10.1136/jitc-2020-001235

Cite this

Neelapu, S. S., Adkins, S., Ansell, S. M., Brody, J., Cairo, M. S., Friedberg, J. W., Kline, J. P., Levy, R., Porter, D. L., Van Besien, K., Werner, M., & Bishop, M. R. (2020). Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma. Journal for immunotherapy of cancer, 8(2), Article e001235. https://doi.org/10.1136/jitc-2020-001235

Neelapu, SS, Adkins, S, Ansell, SM, Brody, J, Cairo, MS, Friedberg, JW, Kline, JP, Levy, R, Porter, DL, Van Besien, K, Werner, M & Bishop, MR 2020, 'Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma', Journal for immunotherapy of cancer, vol. 8, no. 2, e001235. https://doi.org/10.1136/jitc-2020-001235

@article{3eda5122bcb14cf0aa69e707424cc404,

title = "Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma",

abstract = "The recent development and clinical implementation of novel immunotherapies for the treatment of Hodgkin and non-Hodgkin lymphoma have improved patient outcomes across subgroups. The rapid introduction of immunotherapeutic agents into the clinic, however, has presented significant questions regarding optimal treatment scheduling around existing chemotherapy/radiation options, as well as a need for improved understanding of how to properly manage patients and recognize toxicities. To address these challenges, the Society for Immunotherapy of Cancer (SITC) convened a panel of experts in lymphoma to develop a clinical practice guideline for the education of healthcare professionals on various aspects of immunotherapeutic treatment. The panel discussed subjects including treatment scheduling, immune-related adverse events (irAEs), and the integration of immunotherapy and stem cell transplant to form recommendations to guide healthcare professionals treating patients with lymphoma.",

keywords = "antineoplastic protocols, guidelines as topic, hematologic neoplasms, immunotherapy",

author = "Neelapu, {Sattva S.} and Sherry Adkins and Ansell, {Stephen M.} and Joshua Brody and Cairo, {Mitchell S.} and Friedberg, {Jonathan W.} and Kline, {Justin P.} and Ronald Levy and Porter, {David L.} and {Van Besien}, Koen and Michael Werner and Bishop, {Michael R.}",

year = "2020",

month = dec,

day = "24",

doi = "10.1136/jitc-2020-001235",

language = "English (US)",

volume = "8",

journal = "Journal for immunotherapy of cancer",

issn = "2051-1426",

publisher = "BioMed Central",

number = "2",

}

TY - JOUR

T1 - Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma

AU - Neelapu, Sattva S.

AU - Adkins, Sherry

AU - Ansell, Stephen M.

AU - Brody, Joshua

AU - Cairo, Mitchell S.

AU - Friedberg, Jonathan W.

AU - Kline, Justin P.

AU - Levy, Ronald

AU - Porter, David L.

AU - Van Besien, Koen

AU - Werner, Michael

AU - Bishop, Michael R.

PY - 2020/12/24

Y1 - 2020/12/24

N2 - The recent development and clinical implementation of novel immunotherapies for the treatment of Hodgkin and non-Hodgkin lymphoma have improved patient outcomes across subgroups. The rapid introduction of immunotherapeutic agents into the clinic, however, has presented significant questions regarding optimal treatment scheduling around existing chemotherapy/radiation options, as well as a need for improved understanding of how to properly manage patients and recognize toxicities. To address these challenges, the Society for Immunotherapy of Cancer (SITC) convened a panel of experts in lymphoma to develop a clinical practice guideline for the education of healthcare professionals on various aspects of immunotherapeutic treatment. The panel discussed subjects including treatment scheduling, immune-related adverse events (irAEs), and the integration of immunotherapy and stem cell transplant to form recommendations to guide healthcare professionals treating patients with lymphoma.

AB - The recent development and clinical implementation of novel immunotherapies for the treatment of Hodgkin and non-Hodgkin lymphoma have improved patient outcomes across subgroups. The rapid introduction of immunotherapeutic agents into the clinic, however, has presented significant questions regarding optimal treatment scheduling around existing chemotherapy/radiation options, as well as a need for improved understanding of how to properly manage patients and recognize toxicities. To address these challenges, the Society for Immunotherapy of Cancer (SITC) convened a panel of experts in lymphoma to develop a clinical practice guideline for the education of healthcare professionals on various aspects of immunotherapeutic treatment. The panel discussed subjects including treatment scheduling, immune-related adverse events (irAEs), and the integration of immunotherapy and stem cell transplant to form recommendations to guide healthcare professionals treating patients with lymphoma.

KW - antineoplastic protocols

KW - guidelines as topic

KW - hematologic neoplasms

KW - immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=85098334003&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85098334003&partnerID=8YFLogxK

U2 - 10.1136/jitc-2020-001235

DO - 10.1136/jitc-2020-001235

M3 - Review article

C2 - 33361336

AN - SCOPUS:85098334003

SN - 2051-1426

VL - 8

JO - Journal for immunotherapy of cancer

JF - Journal for immunotherapy of cancer

IS - 2

M1 - e001235

ER -

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this